Monogram Technologies Inc. (MGRM)

Compare

2.7350

-0.0850

(-3.01%)

As of 12:45:36 PM EDT. Market Open.

Monogram Technologies Partners with Urvin to Launch an Exclusive, Verified Shareholder Community

AUSTIN, TX / ACCESS Newswire / March 20, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, is pleased to announce ...

ACCESS Newswire 13 days ago

MGRM
-3.01%
MGRM: Monogram Receives Clearance from the FDA on its 510(k) Submission for its mBôs TKA System.

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT On March 17, 2025, Monogram (NASDAQ:MGRM) announced that the FDA has granted 510(k) clearance for its Monogram mBôs TKA System. This determination means that the company can move forward with upgrades and begin the commercialization process. The mBôs TKA System is designed to deliver safety, efficiency, and accuracy in

Zacks Small Cap Research 14 days ago

MGRM
-3.01%
Monogram Technologies And Two More Penny Stocks To Watch

As the U.S. stock market rebounds from a recent downturn, with major indices like the Dow Jones and S&P 500 showing signs of recovery, investors are keenly observing potential opportunities across various sectors. Penny stocks, often associated with smaller or emerging companies, continue to capture interest despite being considered a niche investment area today. By focusing on those with strong financial health and clear growth prospects, these stocks can present unique opportunities for...

Simply Wall St. 16 days ago

SES

SES-WS

SANA
Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System

Monogram May Market the Monogram mBôs™ TKA System, Subject to the Requirements of the Federal Food, Drug, and Cosmetic Act (the Act). The Company is Preparing for Commercialization and Evaluating Strategies to Support the Adoption of its ...

ACCESS Newswire 17 days ago

MGRM
-3.01%
MGRM: Monogram Technologies Reports 4th Quarter and Full Year 2024 Results

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT 4th Quarter and Full Year 2024 Financial Results Monogram (NASDAQ:MGRM) reported 4th quarter and full year 2024 financial results on March 12th which were largely in line with our expectations. Research and development expenses for 2024 were $8.8 million compared to $10.6 million in the prior year period. The R&D decrease was

Zacks Small Cap Research 21 days ago

MGRM
-3.01%
CORRECTION: Monogram Technologies Reports Full Year 2024 Financial Results

This Press Release is Acting as a Correction to the Financial Tables in the Previous Release Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Management to Host Business Update ...

ACCESS Newswire 21 days ago

MGRM
-3.01%
Monogram Technologies Reports Full Year 2024 Financial Results

Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Management to Host Business Update Conference Call on Wednesday, March 12, 2025, at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESS ...

ACCESS Newswire 21 days ago

MGRM
-3.01%
Monogram Technologies to Participate in the 37th Annual ROTH Conference in California March 16-18, 2025

AUSTIN, TX / ACCESS Newswire / March 5, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced that ...

ACCESS Newswire 29 days ago

MGRM
-3.01%
Monogram Technologies to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday, March 12, 2025 at 4:30 p.m. Eastern Time

AUSTIN, TX / ACCESS Newswire / February 27, 2025 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference ...

ACCESS Newswire last month

MGRM
-3.01%
MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Price Target of $6.00.

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Regulatory Update On February 26, 2025, Monogram (NASDAQ:MGRM) announced an update regarding its 510(k) premarket filing submission to the FDA for the company's mBôs TKA System. The company stated it had completed all supplemental testing and submitted its formal response to the Additional Information Request (AIR) by the FDA

Zacks Small Cap Research last month

MGRM
-3.01%
SHALBY.NS
Monogram Technologies Provides Regulatory Update on mBôs TKA System and Clinical Trial Preparation in India

Company has Completed all Supplemental Testing and has Submitted its Formal Response to the FDA's Additional Information Request (AIR) Investigator Meeting and Clinical Trial Training Held at the Shalby Hospital in Ahmedabad, India AUSTIN, TX / ACCESS ...

ACCESS Newswire last month

MGRM
-3.01%
Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA

Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today provided an update from its Submission Issue Request (SIR) meeting ...

ACCESS Newswire 3 months ago

MGRM
-3.01%
Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million

Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, today announced completed purchases of MGRM common stock on the open ...

ACCESS Newswire 3 months ago

MGRM
-3.01%
MGRM: Monogram’s Potential for Profitable Long-Term Growth Supports Price Target of $6.00.

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT Monogram (NASDAQ:MGRM) reported 3rd quarter 2024 financial results on November 14th which were largely in line with expectations. Research and development expenses for the quarter ending September 30, 2024 were $2.2 million compared to $2.7 million in the prior year period. The R&D decrease was primarily due to the company

Zacks Small Cap Research 4 months ago

MGRM
-3.01%
Will Monogram Technologies (NASDAQ:MGRM) Spend Its Cash Wisely?

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 4 months ago

MGRM
-3.01%
Monogram Technologies Reports Third Quarter 2024 Financial Results

Closed an Upsized and Oversubscribed $13 Million Public Offering to Fund Near-term Commercialization Milestones Management to Host Business Update Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time AUSTIN, TX / ACCESSWIRE / November ...

ACCESS Newswire 4 months ago

MGRM
-3.01%
Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

AUSTIN, TX / ACCESSWIRE / November 12, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will hold a conference ...

ACCESS Newswire 4 months ago

MGRM
-3.01%
MGRM: Monogram Announces it has Received an Additional Information Request (AIR) from the FDA Regarding its Recent 510(k) Submission.

By Thomas Kerr, CFA NASDAQ:MGRM READ THE FULL MGRM RESEARCH REPORT FDA Response to 510(k) Filing On October 6, 2024, Monogram (NASDAQ:MGRM) announced it had received an Additional Information Request (“AIR”) from the U.S. Food and Drug Administration (“FDA”) on September 30, 2024, regarding its 510(k) premarket filing submission for the semi-active mBôs TKA System. The application was submitted

Zacks Small Cap Research 4 months ago

MGRM
-3.01%
Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024

Award from Medical Tech Outlook Highlights Monogram's mBôs TKA System AUSTIN, TX / ACCESSWIRE / October 29, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health ...

ACCESS Newswire 5 months ago

MGRM
-3.01%
Monogram Technologies to Present at the LD Micro Main Event XVII Conference on Wednesday October 30, 2024

AUSTIN, TX / ACCESSWIRE / October 16, 2024 / Monogram Technologies Inc. (NASDAQ:MGRM) ("Monogram" or the "Company"), an AI-driven robotics company focused on improving human health with an initial focus on orthopedic surgery, will attend the LD Micro ...

ACCESS Newswire 5 months ago

MGRM
-3.01%

Performance Overview

Return	MGRM	S&P 500 (^GSPC)
YTD	+15.40%	-7.05%
1-Year	+17.38%	+4.90%
3-Year	-73.05%	+20.26%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Monogram Technologies Inc. (MGRM)

Monogram Technologies Partners with Urvin to Launch an Exclusive, Verified Shareholder Community

MGRM: Monogram Receives Clearance from the FDA on its 510(k) Submission for its mBôs TKA System.

Monogram Technologies And Two More Penny Stocks To Watch

Monogram Technologies Announces FDA 510(k) Clearance for the Monogram mBôsTM TKA System

MGRM: Monogram Technologies Reports 4th Quarter and Full Year 2024 Results

CORRECTION: Monogram Technologies Reports Full Year 2024 Financial Results

Monogram Technologies Reports Full Year 2024 Financial Results

Monogram Technologies to Participate in the 37th Annual ROTH Conference in California March 16-18, 2025

Monogram Technologies to Host Fourth Quarter and Full Year 2024 Results Conference Call on Wednesday, March 12, 2025 at 4:30 p.m. Eastern Time

MGRM: Monogram’s Potential for 2025 Commercialization of its mBôs Total Knee Arthroplasty Robotic System Supports Price Target of $6.00.

Monogram Technologies Provides Regulatory Update on mBôs TKA System and Clinical Trial Preparation in India

Monogram Technologies Provides 510(k) Submission Update Following Positive Meeting with FDA

Monogram Technologies Announces Management and Related Parties Complete Open Market Purchases of MGRM Common Stock Totaling $1 Million

MGRM: Monogram’s Potential for Profitable Long-Term Growth Supports Price Target of $6.00.

Will Monogram Technologies (NASDAQ:MGRM) Spend Its Cash Wisely?

Monogram Technologies Reports Third Quarter 2024 Financial Results

Monogram Technologies to Host Third Quarter 2024 Results Conference Call on Tuesday, November 19, 2024 at 4:30 p.m. Eastern Time

MGRM: Monogram Announces it has Received an Additional Information Request (AIR) from the FDA Regarding its Recent 510(k) Submission.

Monogram Technologies Named Orthopedic Joint Replacement Company of the Year 2024

Monogram Technologies to Present at the LD Micro Main Event XVII Conference on Wednesday October 30, 2024

Performance Overview